[Merck KGaA Q3 2026 Earnings Call] Merck Raises Guidance for Third Time as Electronics Surges 13%, But Warns of Steep Mavenclad Decline
Merck KGaA reported Q3 2026 net sales of €5.4bn, up 5.8% YoY, and raised full-year guidance for the third time, citing strong Electronics growth of 13% and Life Science growth of 6.1%. However, the company warned of a steep decline in Mavenclad sales and tougher comparables ahead. Management expects full-year organic sales growth of 3%-4% and EPS pre of €8.30-€8.70.
How this was made
The 30-second read
Why it matters
The guidance raise is a fresh, material disclosure for a large-cap pharma, likely prompting revaluation by investors.
Market read
Guidance raise for Merck KGaA provides new actionable data, likely influencing European pharma stocks and broader market sentiment.
What to watch
The divestiture of the CDMO business and pending Bio-Techne acquisition may introduce integration risks not reflected in the guidance.
Background
Merck KGaA reported Q3 2026 results, highlighting strong electronics growth, life-science performance, and a raised full-year outlook, while warning of a steep decline in its multiple sclerosis drug Mavenclad.
Market effects
Higher guidance may lift European pharma sector and related life-science equipment suppliers.
Positive for German equities and broader DAX index.
Adds to global pharma earnings momentum, could influence investor sentiment on biotech stocks worldwide.
Counterpoint
Mavenclad's steep U.S. sales decline and upcoming phasing effects could pressure margins, suggesting caution.
Key entities
- companyMerck KGaA
German pharmaceutical and life-sciences company reporting Q3 results and raising guidance.
- companySilence Therapeutics
Target of Merck's announced acquisition.
- companyLonza
Acquirer of Merck's CDMO business.
